Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 7/20 | 0.43 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14894295 | 0.93 | BTK (0.42) | BRAFBTKITKROCK2RET | |
| SCHEMBL14894215 | 0.89 | BTK (0.41) | BRAFBTKITKROCK2RET | |
| SCHEMBL14907685 | 0.89 | BTK (0.41) | BRAFBTKITKROCK2RET | |
| SCHEMBL14894031 | 0.88 | VCP (0.50) | BRAFBTKROCK2SMN1; SMN2L3MBTL1 | |
| SCHEMBL14894229 | 0.87 | BRAF (0.42) | BRAFBTKROCK2SMN1; SMN2L3MBTL1 | |
| SCHEMBL14894393 | 0.86 | BTK (0.42) | BRAFBTKROCK2SMN1; SMN2L3MBTL1 | |
| SCHEMBL14894183 | 0.85 | NPC1 (0.42) | BRAFROCK2AURKANPC1KDR | |
| SCHEMBL14907797 | 0.83 | BTK (0.49) | BTKITKSMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL14907650 | 0.82 | AURKA (0.48) | BRAFBTKROCK2SMN1; SMN2L3MBTL1 | |
| SCHEMBL14894109 | 0.82 | NUDT1 (0.39) | BRAFBTKITKROCK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| EP-2771011-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296204-A1 | CHEMICAL COMPOUNDS | DNMT1, DNMT3A, DNMT3B | BRAF 1473/4885BTK 418/4885ITK 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.